Scholarlink

<p>Sjögren&#xa0;disease (SjD) is a chronic inflammatory, multisystem autoimmune disease, with renal involvement reported in 4–30% of patients. The B cell pathway plays a crucial role in the pathogenesis of SjD, particularly through mediators such as B cell activating factor (BAFF, also known as B lymphocyte stimulator [BLyS]) and proliferation-inducing ligand (APRIL), which are key targets for the treatment of SjD. As a novel dual-target biologic, telitacicept inhibits both BLyS and APRIL cytokines, thereby improving immunoglobulin levels and reducing Sjögren’s syndrome disease activity index (ESSDAI) scores. These effects are important for studying the pathogenesis, treatment, and long-term prognosis of patients with SjD. In this review, we discuss the roles of telitacicept in patients with SjD and renal involvement, highlighting its potential to improve disease activity and renal outcomes, and suggest directions for future therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Role and perspectives of telitacicept in Sjögren disease combined with renal involvement

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月2日

查看全文
  • Xiaoya Wang,
  • Hongyu Yu,
  • Yue Wang,
  • Xuehong Lu

摘要

Sjögren disease (SjD) is a chronic inflammatory, multisystem autoimmune disease, with renal involvement reported in 4–30% of patients. The B cell pathway plays a crucial role in the pathogenesis of SjD, particularly through mediators such as B cell activating factor (BAFF, also known as B lymphocyte stimulator [BLyS]) and proliferation-inducing ligand (APRIL), which are key targets for the treatment of SjD. As a novel dual-target biologic, telitacicept inhibits both BLyS and APRIL cytokines, thereby improving immunoglobulin levels and reducing Sjögren’s syndrome disease activity index (ESSDAI) scores. These effects are important for studying the pathogenesis, treatment, and long-term prognosis of patients with SjD. In this review, we discuss the roles of telitacicept in patients with SjD and renal involvement, highlighting its potential to improve disease activity and renal outcomes, and suggest directions for future therapeutic strategies.